These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 31399774

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
    Schmidt HH, Wixner J, Planté-Bordeneuve V, Muñoz-Beamud F, Lladó L, Gillmore JD, Mazzeo A, Li X, Arum S, Jay PY, Adams D, Patisiran Post-LT Study Group.
    Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
    [Abstract] [Full Text] [Related]

  • 24. A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis.
    Coelho T, Adams D, Conceição I, Waddington-Cruz M, Schmidt HH, Buades J, Campistol J, Berk JL, Polydefkis M, Wang JJ, Chen J, Sweetser MT, Gollob J, Suhr OB.
    Orphanet J Rare Dis; 2020 Jul 08; 15(1):179. PubMed ID: 32641071
    [Abstract] [Full Text] [Related]

  • 25. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D, Obici L, Berk JL, Ando Y, Aldinc E, White MT, Adams D.
    Amyloid; 2023 Mar 08; 30(1):49-58. PubMed ID: 36120830
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial.
    Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J.
    Muscle Nerve; 2022 Oct 08; 66(4):438-446. PubMed ID: 35799473
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study.
    Lin KP, Yang CC, Lee YC, Lee MJ, Vest J, Sweetser MT, White MT, Badri P, Hsieh ST, Chao CC.
    J Formos Med Assoc; 2024 Sep 08; 123(9):975-984. PubMed ID: 38548524
    [Abstract] [Full Text] [Related]

  • 32. Responder analysis for neuropathic impairment and quality-of-life assessment in patients with hereditary transthyretin amyloidosis with polyneuropathy in the NEURO-TTR study.
    Yarlas A, Lovley A, Brown D, Kosinski M, Vera-Llonch M.
    J Neurol; 2022 Jan 08; 269(1):323-335. PubMed ID: 34125267
    [Abstract] [Full Text] [Related]

  • 33. Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).
    Gonzalez-Duarte A.
    Clin Auton Res; 2019 Apr 08; 29(2):245-251. PubMed ID: 29511897
    [Abstract] [Full Text] [Related]

  • 34. A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium.
    De Bleecker JL, Claeys KG, Delstanche S, Van Parys V, Baets J, Tilleux S, Remiche G.
    Acta Neurol Belg; 2023 Jun 08; 123(3):1029-1037. PubMed ID: 36829087
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. RNA-targeting and gene editing therapies for transthyretin amyloidosis.
    Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, Gillmore J, Fontana M, Passino C, Emdin M.
    Nat Rev Cardiol; 2022 Oct 08; 19(10):655-667. PubMed ID: 35322226
    [Abstract] [Full Text] [Related]

  • 37. Long-term treatment of hereditary transthyretin amyloidosis with patisiran: multicentre, real-world experience in Italy.
    Gentile L, Mazzeo A, Briani C, Casagrande S, De Luca M, Fabrizi GM, Gagliardi C, Gemelli C, Forcina F, Grandis M, Guglielmino V, Iabichella G, Leonardi L, Lozza A, Manganelli F, Mussinelli R, My F, Occhipinti G, Fenu S, Russo M, Romano A, Salvalaggio A, Tagliapietra M, Tozza S, Palladini G, Obici L, Luigetti M.
    Neurol Sci; 2024 Sep 08; 45(9):4563-4571. PubMed ID: 38622453
    [Abstract] [Full Text] [Related]

  • 38. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7.
    Dyck PJB, González-Duarte A, Obici L, Polydefkis M, Wiesman JF, Antonino I, Litchy WJ, Dyck PJ.
    J Neurol Sci; 2019 Oct 15; 405():116424. PubMed ID: 31445300
    [Abstract] [Full Text] [Related]

  • 39. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.
    Neurodegener Dis Manag; 2019 Feb 15; 9(1):5-23. PubMed ID: 30480471
    [Abstract] [Full Text] [Related]

  • 40. Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy.
    Gendre T, Planté-Bordeneuve V.
    Clin Auton Res; 2019 Sep 15; 29(Suppl 1):25-31. PubMed ID: 31506870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.